A 10 year experience in syngeneic murine models
- Murine models with a complete immune system
- Subcutaneous or orthotopic inoculation of tumor cells
- Validated models known for their response to standard treatments and immune response profile
Custom in vivo evaluation of immunotherapy efficacy
- We adapt administration route & schedule to your need
- Weekly reports about anti-tumor response: tumor size, body weight, survival assessed 3 times per week
- Flexible collection of liquid and solid samples
Analysis of tumor-microenvironment & peripheral markers
- Monitoring anti-cancer immune response throughout the study, with satellite mice, bleedings, intra-tumoral biopsies, or tumor microdialysis
- In-house platform for multiplexed immunophenotyping by flow cytometry, digital histopathology, digital spatial profiling (DSP), proteomics, …
- Complete immune system
- Response to standards available
- Immune profiling data available
Why working with Explicyte?
Experts
in Immuno-Oncology
- 150+ in vivo studies already performed
- 25+ papers in high-impact factor journals
- 10 year-experience in custom experimental & analytical strategies
A flexible
approach
- A top-level scientist dedicated to each study direction from experimental plan to final report
- Weekly reports to provide regular updates & adapt experimental strategy
- Comprehensive analytical platform to decipher anti-tumor response
Your contacts
Talk to our team !
Paul Marteau, PharmD (preclinical study director), Imane Nafia, PhD (CSO), Loïc Cerf, MSc (COO), Alban Bessede, PhD (founder, CEO), Jean-Philippe Guégan, PhD (translational study director)
Tell us about your project !
Syngeneic Tumor Models for the In Vivo Assessment Cancer Immunotherapies I Preclinical CRO services in Immuno-Oncology
Over the past 10 years,Explicyte Immuno-Oncology developed a range of syngeneic mouse tumor models for the in vivo evaluation of novel cancer immunotherapies. Our models are based on the subcutaneous or orthotopic implantation of murine tumor cells in immuno-competent mouse. All our models were validated using standard treatments, such as immune checkpoint inhibitors or reference chemotherapies. Anti-tumor efficacy and immune markers are well-characterized in such models.